A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating in vivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which no in vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dis…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gastroparesis caused by non-pharmacologic etiologies is indeed known to affect drug absorption [6, 7].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [6]
In the citing paper
“Application of the BCS in waiving BA/BE requirements is based on premises that if (1) two immediate-release (IR) drug formulations/products behave as oral solutions within the GI tract due to high solubility and rapid dissolution, (ii) no precipitation occurs in the GI tract once the API is dissolved, and (iii) the two IR formulations have the same in vivo dissolution profile under all intestinal”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
In the citing paper
“The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has enjoyed wide use since 1995 as a mechanism for waiving in vivo bioavailability and bioequivalence studies.”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
Citations
Cites
Diffusion, mass transfer in fluid systems
(1997) · Choice Reviews Online · doi:10.5860/choice.35-0927 · Cited by 4,930
Transit of pharmaceutical dosage forms through the small intestine.
Davis, S. S., Hardy, J. G., & Fara, J. W. (1986) · Gut · doi:10.1136/gut.27.8.886 · Cited by 853
The effect of particle size distribution on dissolution rate and oral absorption
HINTZ, R., & JOHNSON, K. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90069-0 · Cited by 331
Amidon, G. L., Sinko, P. J., & Fleisher, D. (1988) · Pharmaceutical Research · doi:10.1023/a:1015927004752 · Cited by 300
Self-citationOh, D.-M., Curl, R. L., & Amidon, G. L. (1993) · Pharmaceutical Research · doi:10.1023/a:1018947113238 · Cited by 253
Self-citationRegional Rectal Perfusion: A New in Vivo Approach to Study Rectal Drug Absorption in Man
Lennernäs, H., Fagerholm, U., Raab, Y., Gerdin, B., & Hällgren, R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016216905197 · Cited by 219
Self-citationOberle, R. L., & Amidon, G. L. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061761 · Cited by 208
Self-citationRegional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man
Lennernäs, H., Ahrenstedt, Ö., Hällgren, R., Knutson, L., Ryde, M., & Paalzow, L. K. (1992) · Pharmaceutical Research · doi:10.1023/a:1015888813741 · Cited by 202
Self-citationPredicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach
Sinko, P. J., Leesman, G. D., & Amidon, G. L. (1991) · Pharmaceutical Research · doi:10.1023/a:1015892621261 · Cited by 178
Self-citationIn Vitro Dissolution Profile of Water-Insoluble Drug Dosage Forms in the Presence of Surfactants
Shah, V. P., Konecny, J. J., Everett, R. L., McCullough, B., Noorizadeh, A. C., & Skelly, J. P. (1989) · Pharmaceutical Research · doi:10.1023/a:1015909716312 · Cited by 162
Self-citation
Research works printed but not linked: 5
- E.M. Topp, Physiological Flow Models for Intestinal Absorption and Plasma Kinetics of Aspirin, Thesis, The University of Michigan (1986).
- G.D. Leesman, P.J. Sinko, and G.L. Amidon, Simulation of Oral Drug Absorption: Gastric Emptying and Gastrointestinal Motility, in: Pharmacokinetics, P.W. Welling and F.L.S. Tse, Editors, Marcel Dekker, Inc., (NY) 1988, Ch 6, p 267.
- V.G. Levich, Physico-Chemical Hydrodynamics, Prentice-Hall, Englewood Cliffs, NJ (1962).
- H.M. Abdou, Dissolution, Bioavailability, & Bioequivalence, A. Gennaro, B. Migdalof, G.L. Hassert and T. Medwick (Eds), Mack Publishing Co., Easton PA (1989).
- The Merck Index, Tenth Edition, Merck & Co., Inc., Rahway, NJ (1983).
Cited by
Items 601–700 of 1,018
Janssens, S., Nagels, S., de Armas, H. N., D’Autry, W., Schepdael, A. V., & den Mooter, G. V. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.11.004 · Cited by 104
Chakraborty, S., Shukla, D., Jain, A., Mishra, B., & Singh, S. K. (2009) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2009.03.047 · Cited by 104
Kossena, G. A., Charman, W. N., Boyd, B. J., & Porter, C. J. H. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20260 · Cited by 104
Regional intestinal drug permeation: Biopharmaceutics and drug development
Lennernäs, H. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.025 · Cited by 103
Self-citationPaaver, U., Heinämäki, J., Laidmäe, I., Lust, A., Kozlova, J., Sillaste, E., Kirsimäe, K., Veski, P., & Kogermann, K. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.12.024 · Cited by 103
Dahan, A., Miller, J. M., Hilfinger, J. M., Yamashita, S., Yu, L. X., Lennernäs, H., & Amidon, G. L. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100175a · Cited by 102
Self-citationEffects of the Preparation Process on the Properties of Amorphous Solid Dispersions
Huang, S., & Williams, R. O. (2017) · AAPS PharmSciTech · doi:10.1208/s12249-017-0861-7 · Cited by 103
Vithani, K., Jannin, V., Pouton, C. W., & Boyd, B. J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.008 · Cited by 113
Izgelov, D., Shmoeli, E., Domb, A. J., & Hoffman, A. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119201 · Cited by 110
Design and Evaluation of Self-Nanoemulsifying Drug Delivery System of Flutamide
Jyothi, B. J., & Sreelakshmi, K. (2011) · Journal of Young Pharmacists · doi:10.4103/0975-1483.76413 · Cited by 114
“As solubility and permeability are considered prerequisites to oral absorption, many of these drugs exhibit poor and variable bioavailability.[1] Such drugs may be recognized by a highdose-to-solubility ratio, and bioavailability is frequently increased by coadministration of food.”
BackgroundPhysicochemical Properties and Stability of Two Differently Prepared Amorphous Forms of Simvastatin
Graeser, K. A., Strachan, C. J., Patterson, J. E., Gordon, K. C., & Rades, T. (2008) · Crystal Growth & Design · doi:10.1021/cg700913m · Cited by 103
Recent advances in liposomal dry powder formulations: preparation and evaluation
Misra, A. R., Jinturkar, K., Patel, D. H., Lalani, J., & Chougule, M. B. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802652309 · Cited by 104
“2 In vitro lung epithelial cell models The in vitro cultured cell models are highly accepted and used in biopharmaceutical sciences to predict the absorption of test molecules from measurements of their apparent permeability coefficients (Papp) obtained from the in vitro cell monolayer model, alongside their solubilit…”
BackgroundOral biopharmaceutics tools – Time for a new initiative – An introduction to the IMI project OrBiTo
Lennernäs, H., Aarons, L., Augustijns, P., Beato, S., Bolger, M., Box, K., Brewster, M., Butler, J., Dressman, J., Holm, R., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.10.012 · Cited by 99
Self-citationOvercoming poor permeability: translating permeation enhancers for oral peptide delivery
Maher, S., & Brayden, D. J. (2011) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2011.11.006 · Cited by 107
Dalvi, S. V., & Davé, R. N. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.12.026 · Cited by 102
Cook, J., Addicks, W. J., & Wu, Y. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9036-5 · Cited by 102
Newby, D., Freitas, A. A., & Ghafourian, T. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.12.006 · Cited by 112
“Dose number is used to define high and low solubility for the BCS system [4,42].”
BackgroundMethodResultInfluentialDeBoyace, K., & Wildfong, P. L. D. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.03.029 · Cited by 105
Couillaud, B. M., Espeau, P., Mignet, N., & Corvis, Y. (2018) · ChemMedChem · doi:10.1002/cmdc.201800612 · Cited by 101
Sodeifian, G., & Sajadian, S. A. (2018) · Process Safety and Environmental Protection · doi:10.1016/j.cherd.2018.12.020 · Cited by 101
Preparation and evaluation of self-microemulsifying drug delivery system of baicalein
Liu, W., Tian, R., Hu, W., Jia, Y., Jiang, H., Zhang, J., & Zhang, L. (2012) · Fitoterapia · doi:10.1016/j.fitote.2012.08.021 · Cited by 101
Martinez, M. N. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00071-6 · Cited by 101
Tuleu, C., Newton, M. J., Rose, J. M., Euler, D. H., Saklatvala, R., Clarke, A., & Booth, S. W. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20068 · Cited by 101
Development of a screening method for co-amorphous formulations of drugs and amino acids
Kasten, G., Grohganz, H., Rades, T., & Löbmann, K. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.08.022 · Cited by 101
Jejunal Absorption and Metabolism of R/S-Verapamil in Humans
Sandström, R., Karlsson, A., Knutson, L., & Lennernäs, H. (1998) · Pharmaceutical Research · doi:10.1023/a:1011916329863 · Cited by 101
Self-citationImproved solubility and dissolution rate of piroxicam using gelucire 44/14 and labrasol
Karataş, A., Yüksel, N., & Baykara, T. (2005) · Il Farmaco · doi:10.1016/j.farmac.2005.04.014 · Cited by 100
“[2] piroxicam is a class 2 drug, characterized by low solubility–high permeability.”
BackgroundEnhanced Oral Bioavailability and Antioxidant Profile of Ellagic Acid by Phospholipids
Murugan, V., Mukherjee, K., Maiti, K., & Mukherjee, P. K. (2009) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf8037105 · Cited by 98
The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs
Mwambete, K. D., Torrado, S., Cuesta-Bandera, C., Ponce‐Gordo, F., & Torrado, J. J. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.11.030 · Cited by 100
Predicting Drug Absorption: How Nature Made It a Difficult Problem
Burton, P. S., Goodwin, J. T., Vidmar, T. J., & Amore, B. M. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035006 · Cited by 108
“High-permeability drugs are absorbed to the extent of 90% or greater in human (Amidon et al., 1995).”
BackgroundSolubility Advantage of Tenoxicam Phenolic Cocrystals Compared to Salts
Bolla, G., Sanphui, P., & Nangia, A. K. (2013) · Crystal Growth & Design · doi:10.1021/cg4000457 · Cited by 100
Wang, C., Tong, Q., Hou, X., Hu, S., Fang, J., & Sun, C. C. (2016) · Crystal Growth & Design · doi:10.1021/acs.cgd.6b00591 · Cited by 104
Amann, L. C., Gandal, M. J., Lin, R., Liang, Y., & Siegel, S. J. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0152-4 · Cited by 99
“However, correlation analysis for oral medications has long been established and widely accepted ( 28 ).”
BackgroundQattan, M. Y., Khan, M. I., Alharbi, S. H., Verma, A. K., Al‐Saeed, F. A., Alduwish, M. A., & Areefy, A. A. A. (2022) · Molecules · doi:10.3390/molecules27248864 · Cited by 108
Kovačević, I., Parojčić, J., Homšek, I., Tubić-Grozdanis, M., & Langguth, P. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800128y · Cited by 98
A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers
Ganta, S., Deshpande, D., Korde, A., & Amiji, M. M. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.497971 · Cited by 109
Kluge, J., Fusaro, F., Casas, N., Mazzotti, M., & Muhrer, G. (2009) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2009.05.010 · Cited by 107
Yano, K., Masaoka, Y., Kataoka, M., Sakuma, S., & Yamashita, S. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21919 · Cited by 99
Di, L., Feng, B., Goosen, T. C., Lai, Y., Steyn, S. J., Varma, M. V. S., & Obach, R. S. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054031 · Cited by 107
“(Amidon et al., 1995; CDER/FDA, 2000; Yu et al., 2002).”
Tubić-Grozdanis, M., Bolger, M. B., & Langguth, P. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9023-x · Cited by 99
“Nondimensional biopharmaceutical compound characterization numbers ( 1 )”
BackgroundLi, Z., & Matzger, A. J. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00843 · Cited by 99
Protein Digestion of Baby Foods: Study Approaches and Implications for Infant Health
Gan, J., Bornhorst, G. M., Henrick, B. M., & German, J. B. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700231 · Cited by 103
“The relationship of in vitro dissolution and in vivo bioavailability has been studied extensively in pharmaceutics, which has advanced drug discoveries [108, 109].”
BackgroundSjögren, E., Thörn, H., & Tannergren, C. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00861 · Cited by 98
Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited
Al‐Saffar, A., Lennernäs, H., & Hellström, P. M. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13617 · Cited by 97
Self-citationSalunke, S., O’Brien, F., Tan, D. C. T., Harris, D., Math, M.-C., Ariën, T., Klein, S., & Timpe, C. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114507 · Cited by 98
Lenz, E., Jensen, K. T., Blaabjerg, L. I., Knop, K., Grohganz, H., Löbmann, K., Rades, T., & Kleinebudde, P. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.07.011 · Cited by 98
Sanganwar, G. P., & Gupta, R. B. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.041 · Cited by 99
Biopharmaceutics Classification System: Validation and Learnings of an in Vitro Permeability Assay
Thiel-Demby, V. E., Humphreys, J. E., Williams, L. A. S. J., Ellens, H. M., Shah, N., Ayrton, A. D., & Polli, J. W. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800122b · Cited by 98
Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps
Testa, B. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.620 · Cited by 117
“Indeed, and as made explicit by the biopharmaceutics classification scheme (BCS) [19], solubility is one of the main factors influencing oral absorption.”
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024) · Drug Safety · doi:10.1007/s40264-023-01392-3 · Cited by 97
“Gastroparesis caused by non-pharmacologic etiologies is indeed known to affect drug absorption [6, 7].”
BackgroundAmino acids and its pharmaceutical applications: A mini review
Bongioanni, A., Bueno, M. S., Mezzano, B. A., Longhi, M. R., & Garnero, C. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121375 · Cited by 97
Hens, B., Brouwers, J., Corsetti, M., & Augustijns, P. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.05.023 · Cited by 100
Intestinal permeability of metformin using single-pass intestinal perfusion in rats
Song, N.-N. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i25.4064 · Cited by 97
Solanki, N. G., Lam, K., Tahsin, M., Gumaste, S. G., Shah, A. V., & Serajuddin, A. T. M. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.058 · Cited by 96
Schneckener, S., Grimbs, S., Hey, J., Menz, S., Osmers, M., Schaper, S., Hillisch, A., & Göller, A. H. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00460 · Cited by 95
Tsume, Y., & Amidon, G. L. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100053q · Cited by 103
Self-citationAdvanced Technologies for Oral Controlled Release: Cyclodextrins for Oral Controlled Release
Salústio, P. J., Pontes, P., Conduto, C., Sanches, I., Carvalho, C., Arrais, J., & Cabral-Marques, H. M. (2011) · AAPS PharmSciTech · doi:10.1208/s12249-011-9690-2 · Cited by 113
Marasini, N., Yan, Y. D., Poudel, B. K., Choi, H., Yong, C. S., & Kim, J. O. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23333 · Cited by 102
A Critical Appraisal of Solubility Enhancement Techniques of Polyphenols
Kaur, H., & Kaur, G. (2014) · Journal of Pharmaceutics · doi:10.1155/2014/180845 · Cited by 112
“Poor aqueous solubility and low dissolution rates of polyphenols contribute to their insufficient bioavailability [6].”
BackgroundChieng, N., Hubert, M., Saville, D. J., Rades, T., & Aaltonen, J. (2009) · Crystal Growth & Design · doi:10.1021/cg801253f · Cited by 96
Dahan, A., West, B. T., & Amidon, G. L. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.10.013 · Cited by 97
Self-citationNiclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities
Barbosa, E. J., Löbenberg, R., de Araújo, G. L. B., & Bou‐Chacra, N. A. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.05.004 · Cited by 100
LbL coated microcapsules for delivering lipid-based drugs
Shchukina, E. M., & Shchukin, D. G. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.03.009 · Cited by 95
Pham‐The, H., Garrigues, T., Bermejo, M., González‐Álvarez, I., Cruz‐Monteagudo, M., & Cabrera‐Pérez, M. Á. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4000585 · Cited by 103
Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds
Elgart, A., Cherniakov, I., Aldouby, Y., Domb, A. J., & Hoffman, A. (2012) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2012.01.007 · Cited by 102
“Various ipospheres have been used for the controlled delivery of differnt types of drugs including anti-inflammatory compounds, local nesthetics, antibiotics, and anticancer agents, as well as carriers f vaccines and adjuvants (Domb, 2006; Amselem, 1996; Amselem t al., 1992b,a).”
MethodSuenderhauf, C., & Parrott, N. J. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0911-5 · Cited by 107
“Bile salt concentrations play a considerable role in absorption of Griseofulvin and other BCS class II compounds (142).”
InfluentialManadas, R., Pina, M. E., & Veiga, F. (2002) · Revista Brasileira de Ciência do Solo · doi:10.1590/s1516-93322002000400002 · Cited by 177
de Sousa, F. M. B. T., do Nascimento, C. C. S., Ferreira, D., Reis, S., & Costa, P. C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114969 · Cited by 106
The effects of excipients on transporter mediated absorption
Goole, J., Lindley, D. J., Roth, W. J., Carl, S. M., Amighi, K., Kauffmann, J., & Knipp, G. T. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.04.019 · Cited by 111
Classification of Drug Permeability with a Caco-2 Cell Monolayer Assay
Volpe, D. A., Faustino, P. J., Ciavarella, A. B., Asafu-Adjaye, E. B., Ellison, C. D., Yu, L. X., & Hussain, A. S. (2007) · Clinical Research and Regulatory Affairs · doi:10.1080/10601330701273669 · Cited by 94
How good are the crystallisation methods for co-crystals? A comparative study of piroxicam
Fucke, K., Myz, S. A., Шахтшнейдер, Т. П., Boldyreva, E. V., & Griesser, U. J. (2012) · New Journal of Chemistry · doi:10.1039/c2nj40093f · Cited by 94
Wu, C., Wang, Chen, B., Quan, Q., Li, Wu, Dian, Dong, D., & Li (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s37650 · Cited by 94
“Carbamazepine, an effective antiepileptic agent with low solubility (113 μg/mL, 25°C)(26) and high permeability, is designated as a class II agent according to the Biopharmaceutic Classification System.(27) Given that dissolution of poorly water-soluble drugs like carbamazepine is the rate-limiting step for absorption…”
Controlled liquid antisolvent precipitation using a rapid mixing device
Beck, C., Dalvi, S. V., & Davé, R. N. (2010) · Chemical Engineering Science · doi:10.1016/j.ces.2010.04.001 · Cited by 94
Transformation of acidic poorly water soluble drugs into ionic liquids
Balk, A., Wiest, J. M., Widmer, T., Galli, B., Holzgrabe, U., & Meinel, L. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.04.034 · Cited by 94
The BCS, BDDCS, and Regulatory Guidances
Chen, M.-L., Amidon, G. L., Benet, L. Z., Lennernas, H., & Yu, L. X. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0438-1 · Cited by 93
“The BCS (Biopharmaceutics Classification System), based on aqueous solubility and intestinal permeability, has been widely used since 1995 to predict drug absorption during the course of pharmaceutical development (1).”
BackgroundMethodInfluentialSelf-citationLipidic prodrug approach for improved oral drug delivery and therapy
Marković, M., Ben‐Shabat, S., Keinan, S., Aponick, A., Zimmermann, E. M., & Dahan, A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21533 · Cited by 97
Heigoldt, U., Sommer, F., Daniels, R., & Wagner, K. G. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.05.006 · Cited by 93
IV-IVC considerations in the development of immediate-release oral dosage form
Li, S., He, H., Parthiban, L. J., Yin, H., & Serajuddin, A. T. M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20378 · Cited by 105
Fernandez, S., Chevrier, S., Ritter, N., Mahler, B., Demarne, F., Carrière, F., & Jannin, V. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9906-2 · Cited by 100
“due to motion sickness which belongs to the class 2 of BCS (24).”
BackgroundMethodInfluentialCarrière, F. (2015) · Biochimie · doi:10.1016/j.biochi.2015.11.016 · Cited by 98
Lentz, K. A., Hayashi, J., Lucisano, L. J., & Polli, J. E. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00334-3 · Cited by 93
BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements
Davit, B. M., Kanfer, I., Tsang, Y. C., & Cardot, J.-M. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9877-2 · Cited by 96
Zhang, G.-C., Lin, H.-L., & Lin, S. (2012) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2012.03.039 · Cited by 92
Solid Dispersion Technology As a Strategy to Improve the Bioavailability of Poorly Soluble Drugs
Cid, A. G., Simonazzi, A., Palma, S. D., & Bermúdez, J. M. A. (2019) · Therapeutic Delivery · doi:10.4155/tde-2019-0007 · Cited by 92
Nyamba, I., Lechanteur, A., Semdé, R., & Évrard, B. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.11.004 · Cited by 97
Ahmed, I. S., & Aboul-Einien, M. H. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.05.114 · Cited by 92
Oral cyclosporine A - the current picture of its liposomal and other delivery systems
Czogalla, A. (2008) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-008-0041-6 · Cited by 98
“However, oral administration is a problem in the case of CsA, as it is classified as a Class IV drug under the biopharmaceutics classification system [ 40 ], indicating both low solubility [41] and low permeability [42].”
BackgroundGlibenclamide-loaded self-nanoemulsifying drug delivery system: development and characterization
Singh, S. K., Verma, P. R. P., & Razdan, B. (2010) · Drug Development and Industrial Pharmacy · doi:10.3109/03639040903585143 · Cited by 92
Microwave generated solid dispersions containing Ibuprofen
Moneghini, M., Bellich, B., Baxa, P. A., & Princivalle, F. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.05.026 · Cited by 92
In Vivo Predictive Dissolution: Transport Analysis of the CO2, Bicarbonate In Vivo Buffer System
Krieg, B. J., Taghavi, S. M., Amidon, G. L., & Amidon, G. E. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24108 · Cited by 92
Self-citationMudie, D. M., Shi, Y., Ping, H., Gao, P., Amidon, G. L., & Amidon, G. E. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1803 · Cited by 91
“estimated A/V to be equal to 2/r, where r is the radius of the small intestine [3].”
Self-citationShah, K. U., Chan, L. W., & Wong, T. W. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1384298 · Cited by 95
“Rifampicin (C43H58N4O12) is a high molecular weight borderline class II drug, of which its rate and extent of dissolution are critical for obtaining optimum bioavailability (Amidon et al., 1995).”
BackgroundLIPID-BASED VEHICLE FOR ORAL DRUG DELIVERY
Stuchlík, M., & Žák, S. (2001) · Biomedical Papers · doi:10.5507/bp.2001.008 · Cited by 92
ADME-Space: a new tool for medicinal chemists to explore ADME properties
Bocci, G., Carosati, E., Vayer, P., Arrault, A., Lozano, S., & Cruciani, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-06692-0 · Cited by 96
Microbiome-mediated bile acid modification: Role in intestinal drug absorption and metabolism
Enright, E. F., Griffin, B. T., Gahan, C. G. M., & Joyce, S. A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.009 · Cited by 85
Rostamabadi, H., Falsafi, S. R., Rostamabadi, M. M., Assadpour, E., & Jafari, S. M. (2021) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2021.102384 · Cited by 95
Fu, Q., Sun, J., Ai, X., Zhang, P., Li, M., Wang, Y., Liu, X., Sun, Y. H., Sui, X., Sun, L., et al. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.065 · Cited by 91
Diffusion coefficients in ethanol and in water at 298K: Linear free energy relationships
Hills, E. E., Abraham, M. H., Hersey, A., & Bevan, C. (2011) · Fluid Phase Equilibria · doi:10.1016/j.fluid.2011.01.002 · Cited by 95
Sarode, A. L., Sandhu, H. K., Shah, N. H., Malick, W. A., & Zia, H. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400165b · Cited by 91
Balan, G., Timmins, P., Greene, D. S., & Marathe, P. H. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1071 · Cited by 91
Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous Solid Dispersion
Metre, S., Mukesh, S., Samal, S. K., Chand, M., & Sangamwar, A. T. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01027 · Cited by 90
Metadata
- Authors
- Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R.
- Affiliations
- University of Michigan (US)
- Uppsala University (SE)
- United States Food and Drug Administration (US)
- Therapeutics Systems Research Laboratories (United States) (US)
- Venue
- Pharmaceutical Research
- Published
- 1995-03
- Volume
- 12
- Issue
- 3
- Pages
- 413-420
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1498305210
- Cited by
- 5,430
- References
- 29
- Citations by year
- 2026: 170 · 2025: 201 · 2024: 182 · 2023: 240 · 2022: 266 · 2021: 282 · 2020: 299 · 2019: 241 · 2018: 278 · 2017: 267 · 2016: 283 · 2015: 283 · 2014: 302 · 2013: 296 · 2012: 302
- FWCI
- 26.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- U.S. Food and Drug Administration (FD-01462)
- National Institute of General Medical Sciences (GM 37188, R01GM037188)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- in vitro-in vivo correlation, drug dissolution, bioavailability, gastrointestinal permeability, oral drug absorption, solubility, transport modeling, dissolution profile, surfactants
- MeSH terms
- Biological Availability, Cimetidine, Pharmaceutical Preparations, Gastric Emptying, Jejunum, Mathematics, Models, Theoretical, Permeability, Piroxicam, Solubility, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.